Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2021. Module: SNOMED CT core module
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
4555548014 | Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
4555549018 | Ruxolitinib (as ruxolitinib phosphate) 15 mg oral tablet | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Ruxolitinib | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Ruxolitinib phosphate | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antineoplastic therapeutic role | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 1 | |
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only ruxolitinib in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet | true | Inferred relationship | Existential restriction modifier | ||
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets